@Article{ecn.2010.0198,
AUTHOR = {Yvonne M. Mueller, Peter D. Katsikis},
TITLE = {IL-15 in HIV infection: pathogenic or therapeutic potential?},
JOURNAL = {European Cytokine Network},
VOLUME = {21},
YEAR = {2010},
NUMBER = {3},
PAGES = {219--221},
URL = {http://www.techscience.com/ECN/v21n3/65862},
ISSN = {1952-4005},
ABSTRACT = {Recent studies have shown that interleukin-15 (IL-15) is produced during acute HIV and SIVinfection, and may impact viremia and viral set point. This is further supported by the findings that administra-tion of IL-15 during acute SIV infection dramatically increases viral set point. Although the role of intrinsicIL-15 during chronic infection is much less defined, in vivo administration of IL-15 does not increase viral repli-cation in SIV-infected animals. Recent data also suggest that IL-15 acts, not only on CD8+ T cells and naturalkiller cells, but also on effector memory CD4+ T cells. IL-15 clearly expands very different CD4+ T cell subpo-pulations than IL-2 in SIV-infected animals, and may be useful for the restoration of effector memory CD4+T cells that are depleted early in HIV and SIV infection. Understanding IL-15’s role in SIV infection may helpus to design novel therapeutic approaches to HIV infection.},
DOI = {10.1684/ecn.2010.0198}
}